Ubs Asset Management Americas Inc Mersana Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $80,235 - $111,619	14,201 Added 16.07%	102,575 $601,000
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $168,131 - $298,051	44,955 Added 103.54%	88,374 $352,000
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $51,154 - $69,605	3,852 Added 9.74%	43,419 $589,000
Q1 2021 May 14, 2021	SELL	$15.31 - $26.52 $438,095 - $758,869	-28,615 Reduced 41.97%	39,567 $640,000
Q4 2020 Mar 01, 2021	BUY	$16.84 - $27.59 $88,241 - $144,571	5,240 Added 8.33%	68,182 $1.81 Million
Q3 2020 Nov 13, 2020	BUY	$16.2 - $25.7 $175,251 - $278,022	10,818 Added 20.75%	62,942 $1.17 Million
Q2 2020 Aug 14, 2020	BUY	$5.24 - $23.4 $273,129 - $1.22 Million	52,124 New	52,124 $1.22 Million

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $211M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.